AR060324A1 - Metodos para modular la funcion de la vejiga - Google Patents
Metodos para modular la funcion de la vejigaInfo
- Publication number
- AR060324A1 AR060324A1 ARP070101220A ARP070101220A AR060324A1 AR 060324 A1 AR060324 A1 AR 060324A1 AR P070101220 A ARP070101220 A AR P070101220A AR P070101220 A ARP070101220 A AR P070101220A AR 060324 A1 AR060324 A1 AR 060324A1
- Authority
- AR
- Argentina
- Prior art keywords
- bladder
- independently
- mammal
- methods
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Métodos y composiciones farmacéuticas para la modulacion de la funcion vesical, y en particular, para el mantenimiento del control de la vejiga o el tratamiento de incontinencia urinaria. Reivindicacion 1: Un método para el tratamiento de la incontinencia urinaria en un mamífero, que comprende la administracion, a dicho mamífero, de una cantidad terapéuticamente eficaz de un compuesto de la formula 1 o una sal aceptable para uso farmacéutico de dicho compuesto, donde; === designa un enlace simple o doble; n es 1 o 2; m es 0 o 1; R1 y R2 son independientemente halogeno, -CN, -R, -OR, perfluoralquilo C1-6, u Operfluoralquilo C1-6; cada R es, de manera independiente, hidrogeno o un grupo alquilo C1-6; ligados, para formar un anillo de 4 a 8 miembros, saturado o insaturado, donde dicho anillo está opcionalmente sustituido con 1 a 3 grupos seleccionados de modo independiente de halogeno, R u OR; y R5 y R6 son independientemente, -R.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78545106P | 2006-03-24 | 2006-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR060324A1 true AR060324A1 (es) | 2008-06-11 |
Family
ID=38474526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070101220A AR060324A1 (es) | 2006-03-24 | 2007-03-23 | Metodos para modular la funcion de la vejiga |
Country Status (15)
Country | Link |
---|---|
US (2) | US20070225274A1 (es) |
EP (1) | EP1998782A2 (es) |
KR (1) | KR20080107430A (es) |
CN (1) | CN101405005A (es) |
AR (1) | AR060324A1 (es) |
AU (1) | AU2007230891A1 (es) |
BR (1) | BRPI0709164A2 (es) |
CA (1) | CA2645099A1 (es) |
CL (1) | CL2007000774A1 (es) |
IL (1) | IL193841A0 (es) |
MX (1) | MX2008012105A (es) |
PA (1) | PA8720701A1 (es) |
PE (1) | PE20080125A1 (es) |
TW (1) | TW200806298A (es) |
WO (1) | WO2007112073A2 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GT200500317A (es) * | 2004-11-05 | 2006-10-27 | Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos | |
AR054849A1 (es) * | 2005-07-26 | 2007-07-18 | Wyeth Corp | Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas |
TW200734334A (en) * | 2006-01-13 | 2007-09-16 | Wyeth Corp | Treatment of substance abuse |
KR20080110759A (ko) * | 2006-03-24 | 2008-12-19 | 와이어쓰 | 통증 치료 |
KR20080105104A (ko) * | 2006-03-24 | 2008-12-03 | 와이어쓰 | 우울증 치료를 위한 신규한 치료학적 병용제 |
CL2008002777A1 (es) * | 2007-09-21 | 2010-01-22 | Wyeth Corp | Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario. |
CN102482292B (zh) | 2009-04-23 | 2017-07-18 | Abbvie 公司 | 5‑ht受体的调节剂和其使用方法 |
US8518933B2 (en) * | 2009-04-23 | 2013-08-27 | Abbvie Inc. | Modulators of 5-HT receptors and methods of use thereof |
US8546377B2 (en) * | 2009-04-23 | 2013-10-01 | Abbvie Inc. | Modulators of 5-HT receptors and methods of use thereof |
ES2535490T3 (es) | 2009-05-22 | 2015-05-12 | Abbvie Inc. | Preparación de moduladores de receptores 5-HT |
CN104860951A (zh) * | 2010-05-21 | 2015-08-26 | Abbvie公司 | 5-ht受体的调节剂和其使用方法 |
AU2013314279B2 (en) | 2012-09-14 | 2017-11-02 | AbbVie Deutschland GmbH & Co. KG | Tricyclic quinoline and quinoxaline derivatives |
US20140080813A1 (en) | 2012-09-14 | 2014-03-20 | AbbVie Deutschland GmbH & Co. KG | Tricyclic quinoline and quinoxaline derivatives |
CN103204858A (zh) * | 2013-03-20 | 2013-07-17 | 广州科瑞生物技术有限公司 | 基于酒石酸拆分合成工艺制备新型手性抗焦虑症药物 |
EP3116873B1 (en) | 2014-03-14 | 2018-02-28 | AbbVie Deutschland GmbH & Co. KG | Hexahydrodiazepinoquinolines carrying a cyclic radical |
WO2015136091A1 (en) | 2014-03-14 | 2015-09-17 | AbbVie Deutschland GmbH & Co. KG | Hexahydrodiazepinoquinolines carrying a substituted alkyl radical |
EP3380483A1 (en) | 2015-11-25 | 2018-10-03 | Abbvie Deutschland GmbH & Co. KG | Hexahydropyrazinobenz- or -pyrido-oxazepines carrying an oxygen-containing substituent and use thereof in the treatment of 5-ht2c-dependent disorders |
WO2018175449A1 (en) | 2017-03-21 | 2018-09-27 | AbbVie Deutschland GmbH & Co. KG | Proline amide compounds and their azetidine analogues carrying a specifically substituted benzyl radical |
KR20220041136A (ko) * | 2019-07-30 | 2022-03-31 | 셀릭스 바이오 프라이빗 리미티드 | 항문 및 직장 질환 치료용 조성물 및 방법 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3417101A (en) * | 1964-11-09 | 1968-12-17 | American Home Prod | Fused ring compounds |
US3714149A (en) * | 1969-11-03 | 1973-01-30 | Upjohn Co | Pyridobenzodiazepinones |
US3914250A (en) * | 1974-08-01 | 1975-10-21 | American Home Prod | 1,4-Diazepino{8 6,5,4-jk{9 carbazoles |
US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
NZ314105A (en) * | 1996-02-02 | 1997-12-19 | Sumitomo Pharma | Guanidine derivative substituted with a substituted indole which is peri condensed with a heterocyclic ring |
GB9711643D0 (en) * | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
CO5210925A1 (es) * | 1998-11-17 | 2002-10-30 | Novartis Ag | Derivados de diamino nitroguanidina tetrasustituidos |
IL146582A0 (en) * | 1999-05-21 | 2002-07-25 | Biovitrum Ab | Novel compounds, their use and preparation |
JP3938689B2 (ja) * | 2000-03-16 | 2007-06-27 | エフ.ホフマン−ラ ロシュ アーゲー | Ipアンタゴニストとしてのカルボン酸誘導体 |
US6858604B2 (en) * | 2000-11-03 | 2005-02-22 | Wyeth | Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives |
AR031200A1 (es) * | 2000-11-03 | 2003-09-10 | Wyeth Corp | Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados |
AR031201A1 (es) * | 2000-11-03 | 2003-09-10 | Wyeth Corp | /1,4/diazepino/6,7,1-jk/carbazoles y derivados |
US6777407B2 (en) * | 2000-11-03 | 2004-08-17 | Wyeth | Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives |
DE60106641T2 (de) * | 2000-11-03 | 2005-12-01 | Wyeth | Cyclopenta[b][1,4] diazepino[6,7,1-hi]indole als 5ht2c antagonisten |
EP1343791A2 (en) * | 2000-12-20 | 2003-09-17 | Bristol-Myers Squibb Company | Substituted tetracyclic pyridoindoles as serotonin agonists and antagonists |
US6849619B2 (en) * | 2000-12-20 | 2005-02-01 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
TWI312781B (en) * | 2002-04-25 | 2009-08-01 | [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | |
JP5173190B2 (ja) * | 2004-08-25 | 2013-03-27 | 武田薬品工業株式会社 | 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法 |
AR054849A1 (es) * | 2005-07-26 | 2007-07-18 | Wyeth Corp | Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas |
PE20070549A1 (es) * | 2005-10-17 | 2007-06-15 | Wyeth Corp | Tetrahidroquinolinas, su sintesis e intermediarios |
TW200734334A (en) * | 2006-01-13 | 2007-09-16 | Wyeth Corp | Treatment of substance abuse |
CA2644618A1 (en) * | 2006-03-24 | 2007-10-04 | Wyeth | Methods for treating cognitive and other disorders |
CL2008002777A1 (es) * | 2007-09-21 | 2010-01-22 | Wyeth Corp | Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario. |
-
2007
- 2007-03-23 US US11/728,107 patent/US20070225274A1/en not_active Abandoned
- 2007-03-23 PA PA20078720701A patent/PA8720701A1/es unknown
- 2007-03-23 EP EP07753970A patent/EP1998782A2/en not_active Withdrawn
- 2007-03-23 CA CA002645099A patent/CA2645099A1/en not_active Abandoned
- 2007-03-23 BR BRPI0709164-8A patent/BRPI0709164A2/pt not_active Application Discontinuation
- 2007-03-23 TW TW096110131A patent/TW200806298A/zh unknown
- 2007-03-23 WO PCT/US2007/007387 patent/WO2007112073A2/en active Application Filing
- 2007-03-23 AU AU2007230891A patent/AU2007230891A1/en not_active Abandoned
- 2007-03-23 AR ARP070101220A patent/AR060324A1/es unknown
- 2007-03-23 PE PE2007000318A patent/PE20080125A1/es not_active Application Discontinuation
- 2007-03-23 KR KR1020087023338A patent/KR20080107430A/ko not_active Application Discontinuation
- 2007-03-23 MX MX2008012105A patent/MX2008012105A/es not_active Application Discontinuation
- 2007-03-23 CN CNA2007800092961A patent/CN101405005A/zh active Pending
- 2007-03-23 CL CL200700774A patent/CL2007000774A1/es unknown
-
2008
- 2008-09-02 IL IL193841A patent/IL193841A0/en unknown
-
2009
- 2009-06-05 US US12/479,341 patent/US20090281091A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20070225274A1 (en) | 2007-09-27 |
WO2007112073A3 (en) | 2007-11-29 |
KR20080107430A (ko) | 2008-12-10 |
BRPI0709164A2 (pt) | 2011-06-28 |
PA8720701A1 (es) | 2008-11-19 |
WO2007112073A2 (en) | 2007-10-04 |
PE20080125A1 (es) | 2008-04-07 |
IL193841A0 (en) | 2009-09-22 |
CN101405005A (zh) | 2009-04-08 |
CA2645099A1 (en) | 2007-10-04 |
AU2007230891A1 (en) | 2007-10-04 |
MX2008012105A (es) | 2008-10-03 |
CL2007000774A1 (es) | 2008-03-07 |
US20090281091A1 (en) | 2009-11-12 |
TW200806298A (en) | 2008-02-01 |
EP1998782A2 (en) | 2008-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR060324A1 (es) | Metodos para modular la funcion de la vejiga | |
CL2019002167A1 (es) | Compuesto de la fórmula (ic) o una sal farmacéuticamente aceptable del mismo, o una composición farmacéutica que comprende dicho compuesto o una sal farmacéuticamente aceptable del mismo, y al menos un portador farmacéuticamente aceptable, y su uso en el tratamiento de disautonomía familiar al mejorar el empalme de marn. (divisional solicitud 201701823.) | |
CO2021015698A2 (es) | Moduladores de thr-β y métodos de uso de estos | |
AR120080A1 (es) | Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos | |
AR049399A1 (es) | Difenilimidazopirimidina e -imidazol aminas como inhibidores de b-secretasa y metodo de obtencion de los mismos | |
AR049956A1 (es) | DERIVADOS DE 1,3 - OXAZOLIDIN - 2 - ONA COMO INHIBIDORES DE CETP Y ELEVADORES DEL NIVEL DE LAD-C; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA ATEROSCLEROSIS. | |
AR072508A1 (es) | Inhibidores alfa 7 nicotinicos del receptor de acetilcolina | |
ES2586283T3 (es) | Emulsiones autoconservadas | |
PE20180462A1 (es) | Moduladores cot y metodos de uso de los mismos | |
AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
CO2021015624A2 (es) | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituída, composiciones de estos y métodos de tratamiento con dichos compuestos | |
AR061867A1 (es) | Derivados de (4,5') bipirimidil 6,4' - diamina como inhibidores de proteinquinasa | |
DK0862567T3 (da) | 5-azabicyclo[3.1.0]hexylalkyl-2-piperidoner og-glutarimider som neurokininreceptorantagonister | |
AR056197A1 (es) | Derivados de 7-metilimidazol[1,2-a]piridin-6-il-8-metil-nonamidas como inhibidores de la renina, composciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de la hipertension arterial | |
CO5680439A2 (es) | Derivados de ciclotiocarbamato como moduladores de pr y su uso para el tratamiento de desordenes de la piel | |
BRPI0716069A2 (pt) | composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio | |
AR073524A1 (es) | Piridopirimidinonas inhibidores de pi3k a y m tor | |
FR2903107B1 (fr) | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique | |
ATE537175T1 (de) | Neue piperazino-dihydrothienopyrimidin-derivate | |
SV2006002069A (es) | Procedimiento para la obtención de un compuesto aplicado en el tratamiento de esquizofrenia y/o anomalías de glucorregulación | |
AR065355A1 (es) | Moduladores de lta4h y sus usos | |
UY27503A1 (es) | Nuevos derivados de piperazina | |
CO6321241A2 (es) | Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp) | |
BR0309278A (pt) | Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto | |
HRP20090112T3 (en) | 2- (1h-indolylsulfanyl) -aryl amine derivatives for use in the treatment of affective disorders, pain, adhd and stress urinary incontinence |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |